Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 -2.33%90 PB Ratio is 7.34 as of Sep. 04, 2026, which is 25% below its 10-year median of 9.76. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,692.36 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,216 Biotechnology companies, Concord Biotech ranks worse than 81.74% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-04), Concord Biotech's share price is ₹1414.75. Concord Biotech's Book Value per Share for the quarter that ended in Jun. 2026 was ₹192.81. Hence, Concord Biotech's PB Ratio of today is 7.34.
The historical rank and industry rank for Concord Biotech's PB Ratio or its related term are showing as below:
BOM:543960'
s PB Ratio Range Over the Past 10 Years
Min: 5.27 Med: 9.76 Max: 14.28
Current: 7.87
During the past 7 years, Concord Biotech's highest PB Ratio was 14.28. The lowest was 5.27. And the median was 9.76.
BOM:543960's PB Ratio is ranked worse than 81.74% of 1216
companies
in the Biotechnology industry
Industry Median: 2.945
vs BOM:543960: 7.87
During the past 12 months, Concord Biotech's average Book Value Per Share Growth Rate was 11.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Concord Biotech was 18.80% per year. The lowest was 15.20% per year. And the median was 17.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Concord Biotech PB Ratio Related Terms
Concord Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Concord Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, MRNA: PB Ratio Comparison
For the Biotechnology subindustry, Concord Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Concord Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Concord Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Concord Biotech (BOM:543960) has a PB Ratio of 7.34 as of Sep. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Concord Biotech and its competitors. This is 25% below median its historical median of 9.76. Over the past decade, Concord Biotech's PB Ratio has ranged from 5.27 to 14.28. According to the industry distribution chart, Concord Biotech ranks #994 out of 1216 companies in the Biotechnology industry, placing it in the top 81.7%.
Is Concord Biotech's PB Ratio too high?
Concord Biotech's current PB Ratio of 7.34 is 25% below median its 10-year median of 9.76. Over the past 10 years, this metric has ranged from a low of 5.27 to a high of 14.28. The Biotechnology industry median PB Ratio is 2.95. Concord Biotech's value of 7.34 is 149.2% above this industry median. Based on the distribution chart, Concord Biotech ranks #994 out of 1216 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #994 out of 1216 companies for PB Ratio. This places Concord Biotech in the lower half of its industry. The industry median PB Ratio is 2.95. Concord Biotech's value of 7.34 is 149.2% above this benchmark. Historically, Concord Biotech's own PB Ratio has ranged from 5.27 to 14.28 over the past decade. While the company's 10-year median is 9.76 vs. the industry median of 2.95, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current PB Ratio of 7.34 is 149.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current PB Ratio is 7.34, which is 25% below median its own 10-year median of 9.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,692.36, compared to a current price of ₹1,414.75 — trading 16.4% below its estimated fair value. The current PB Ratio is 7.34, which is 25% below median its 10-year median of 9.76 and 149.2% above the Biotechnology industry median of 2.95. Concord Biotech's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current PB Ratio is 7.34 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,414.75 is trading 16.4% below its estimated GF Value™ of ₹1,692.36.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
PB Ratio: 7.34 (25% below median its 10-year median of 9.76)
GF Value™: ₹1,692.36 vs. price of ₹1,414.75 (16.4% below fair value)
Industry Position: 149.2% above the Biotechnology median (#994 of 1216)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
